Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT02689206
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 103 participants
- Sponsor
- Registry
-
NCT02689206 -
2015-004790-32
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Germany, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02689206. Randomized; double masking; primary purpose treatment. Start 2016-02-17 (actual); primary completion 2017-01-25 (actual). Results posted on 2018-05-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
- Condition
- Anaemia
- Intervention (Drug)
- GSK1278863
- Intervention (Drug)
- GSK1278863 matching Placebo
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct02689206- Content hash
c217d585cd15f920126ea8a9cdb5bba3c549a257a0dbafb4e4cb79ea40960fd7